HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


WEN Class Action Headed For Potential $26M Settlement In California

This article was originally published in The Rose Sheet

Executive Summary

Individuals with documented hair loss or other injuries attributed to use of WEN Cleansing Conditioners could be compensated with payments up to $20,000 apiece under a proposed settlement expected to be entered in California’s Central District at the start of August.

You may also be interested in...

DevaCurl Faces Multiple Class Actions As Latest Brand Linked To Hair Loss

The company maintains that its products are safe, but plaintiffs in proposed class actions allege it has knowingly put consumers at risk of hair loss and other injuries. DevaCurl’s troubles escalated quickly after a former brand ambassador went viral with a 31 January video urging consumers to stop using DevaCurl products and adopt safer alternatives.

WEN Consumers To Begin Filing Claims Under Approved Class Settlement

A class action settlement preliminarily approved in California’s Central District will establish a $26.25m fund for compensating WEN hair-care consumers for purchases and alleged injuries, but the fairness of payments to up to 6 million class members may have to be revisited if more claims are filed than expected. Notices to class members will issue by year-end, and their claims must be submitted by late April 2017.

FDA Divulges Cosmetics Enforcement Data, Notes Hair Loss As ‘Serious’ AE

Momentum this year behind legislative proposals for cosmetics regulatory reform has prompted key Congress members to question FDA about the current oversight system. In a response to the Senate HELP Committee’s chairman, FDA provides a wealth of data on its enforcement activities and confirms hair loss as an adverse event it considers “serious,” if not one currently identified as such by MedWatch’s definition.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts